TCZ is a fully humanized anti-IL-6R antibody approved as therapy for numerous autoimmune diseases, including rheumatoid arthritis (RA), adult-onset Still’s disease, and Castleman disease, as well as for the treatment of systemic JIA, where uveitis is uncommon [10,11]. The gene discussed is IL6R; the disease is rheumatoid arthritis.